SUPPORT LINE
0300 111 1234
Read here the history of Tolvaptan.
To access the latest papers published on Tolvaptan, please visit PubMed website. (The search terms used to show this page of results were 'tolvaptan' AND 'polycystic kidney disease'.)
User Rating: 3 / 5
The European Medicines Agency (EMA) has recommended granting a marketing authorisation to tolvaptan, which now has the brand name: JINARC.
User Rating: 1 / 5
Listen to Dr Donal O'Donoghue, the former National Clinical Director of Kidney Care in England, discuss the Tolvaptan trial and its implications for ADPKD patients. (20 minute video skype chat.)
User Rating: 3 / 5
The Department of Health has asked NICE - the National Institute for Health and Care Excellence - to conduct an appraisal of tolvaptan for treating ADPKD (autosomal dominant polycystic kidney disease). The date of the appraisal meeting will be 1st April 2015.
User Rating: 1 / 5
At the American Society of Nephrology (ASN) meeting on 3 November 2012, Dr Vicente Torrres from the Mayo Clinic, together with research collaborators, reported the results of a 3 year global study known as TEMPO - Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease Outcomes.
RT @kidneycanada: Are you a patient, caregiver or health professional? Join the international @song_initiative Delphi panel to help gain ag…
RT @Mad4MountainsUK: Out leading friends from New Zealand up the classic ledge route on Ben Nevis. All training for Mont Blanc 2019 with th…
Exercise shown to improve symptoms of patients with chronic kidney disease https://t.co/SffPbP87xi
RT @RenalRadar: The latest issue of the RaDaR Newsletter contains information about our compliance with the new General Data Protection Reg…
RT @actiononsalt: PepsiCo Mexico announces reduction of salt, sugar in products https://t.co/KrEAG0YH3Y
RT @kidneycanada: Are you a patient, caregiver or health professional? Join the international @song_initiative Delphi panel to help gain ag…
